Tigecycline is an injectable glycylcycline antibacterial drug. It is a semi-synthetic derivative of minocycline. Tigecycline acts against tetracycline-resistant gram-positive and gram-negative pathogens. It is used to treat infections of the skin, soft tissues and intra-abdominal infections caused by susceptible bacteria. It is injected intravenously. The Tigecycline drug attaches to bacterial ribosomes and stops the production of proteins required for the growth and multiplication of the bacteria. This medicine is also able to overcome typical bacterial resistance to tetracyclines. Its modification at position 9 of its core structure, gives additional steric hindrance to it. Therefore, Tigecycline has a much wider range of activity than conventional tetracyclines. However, it only prevents multiplication of the bacteria; it does not kill the bacteria.